Industries > Pharma > Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033

Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033

Forecasts by Technology (Deep Learning, NLP, Image Processing, Other), by Application (Business Process & Supply Chain, Drug Discovery, Medical Imaging & Diagnostics, Precision Medicine), by End-users (Manufacturers, Contract Research Organisations, Academic & Government Research Institutes) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

PUBLISHED: 23 June 2023
PAGES: 218
PRODUCT CODE: PHA1264

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1264 Categories: , Tags: , , ,

The Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing collaborations among organizations towards drug development enabled by AI
There has been a significant shift in cutting-edge AI technologies at big pharmaceutical companies. Since 2015, there has been a clear change in the public’s image of artificial intelligence, from skepticism to cautious interest to the realization that AI plays a vital role in the new “data-centric” model of innovation. This shift in perception was supported by a number of elements, including: – a flurry of research discoveries and proof-of-concept studies in a variety of AI application use cases; – a number of commercial successes and successfully attained milestones incorporating AI as a key component of research. For instance, in March 2023, Exscientia PLC announced collaboration with Charité – Universitätsmedizin Berlin (Germany) to adopt AI-driven precision medicine platform in haematological cancers. In February 2023, Verily, an Alphabet precision health company, and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) announced that they are collaborating on novel methods for clinical trials looking at therapies for individuals with Major Depressive Disorder (MDD).

Developing interoperability systems is a challenging factor for the market
The capacity of systems and gadgets to communicate and decipher shared data through wired and wireless networks is referred to as interoperability. For all parties involved in the health care ecosystem, including biopharma businesses, it poses a serious challenge. The majority of biopharmaceutical businesses operate across many geographies with numerous diverse IT systems and require access to information from a wide range of IT systems used by healthcare organisations and other partners. The capacity to establish connectivity and communication between devices and IT systems, as well as between data and workflows, is necessary for interoperability. This is done by using consensus standards and protocols to enable secure and transparent data exchange.

The entire biopharma value chain must be improved through the development of interoperable technologies, especially in the area of patient data sharing with consent. Among many other uses, interoperability can assist businesses in communicating with clinicians and patients more effectively, enhancing the supply chain’s ability to track and trace items, enhancing clinical decision support, locating patients, and enhancing drug adherence. To increase workflow efficiency and performance and to eliminate siloes behaviour, interoperability is required.

What Questions Should You Ask before Buying a Market Research Report?
• How is the AI in Biopharmaceutical market evolving?
• What is driving and restraining the AI in Biopharmaceutical market?
• How will each AI in Biopharmaceutical submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each AI in Biopharmaceutical submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading AI in Biopharmaceutical markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the AI in Biopharmaceutical projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of AI in Biopharmaceutical projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the AI in Biopharmaceutical market?
• Where is the AI in Biopharmaceutical market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the AI in Biopharmaceutical market today, and over the next 10 years:
• Our 218-page report provides 90 tables and 137 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the AI in Biopharmaceutical market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising AI in Biopharmaceutical prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company.

Segments Covered in the Report

Technology Outlook
• Deep Learning
• NLP
• Image Processing
• Other Technologies

Application
• Business Process & Supply Chain
• Drug Discovery
• Medical Imaging & Diagnostics
• Precision Medicine

End-users
• Manufacturers
• Contract Research Organizations
• Academic & Government Research Institutes

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 17 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033
Need industry data? Please contact us today.

The report also includes profiles and for some of the leading companies in the AI in Biopharmaceutical Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Alphabet Inc.
• Amgen Inc.
• ConcertAI
• Exscientia
• Insilico Medicine
• Merative (IBM)
• Microsoft
• NVIDIA Corporation
• Schrödinger, Inc.
• Tencent

Overall world revenue for AI in Biopharmaceutical Market, 2023 to 2033 in terms of value the market will surpass US$49.3 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the AI in Biopharmaceutical Market, 2023 to 2033 report help you?
In summary, our 210+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for AI in Biopharmaceutical Market, 2023 to 2033 Market, with forecasts for technology, application, and end-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 17 key national markets – See forecasts for the AI in Biopharmaceutical Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the AI in Biopharmaceutical Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the AI in Biopharmaceutical Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033: Forecasts by Technology (Deep Learning, NLP, Image Processing, Other), by Application (Business Process & Supply Chain, Drug Discovery, Medical Imaging & Diagnostics, Precision Medicine), by End-users (Manufacturers, Contract Research Organisations, Academic & Government Research Institutes) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033

    Download sample pages

    Complete the form below to download your free sample pages for Artificial Intelligence (AI) in Biopharmaceuticals Market Report 2023-2033

      Latest Pharma news

      Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034

      The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.

      23 April 2024

      READ

      Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

      The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

      18 April 2024

      READ

      Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

      The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

      17 April 2024

      READ

      Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

      The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

      12 April 2024

      READ